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ABSTRACT
Reduced bone mineral density (BMD) occurs frequently in children after hematopoietic cell transplantation
(HCT), but therapy for this complication is undefined. To determine the impact of bisphosphonate therapy on
reduced BMD after HCT, we compared baseline and follow-up dual energy X-ray absorptiometry (DEXA)
scans of 48 patients (controls) who received calcium and vitamin D to 18 patients who also received bisphos-
phonate therapy. Among the controls, median annualized increase in standardized BMD (sBMD) was 10%
(range, 26% to 41%), but the deviation of sBMD from normal, as indicated by the Z-score, did not improve
from baseline, 2.46 (range: 5.15 to 1.16) compared to follow-up, 2.79 (range: 5.76 to 0.07). For the
bisphosphonate-treated patients, the median annualized increase in sBMD was 33% (range 3% to 147%, P 
.0002) and the median Z-score improved from 3.57 (range: 5.13 to 0.86) at baseline, to 1.80 (4.89 to
0.47) at follow-up (P  .06). The annualized median change in BMD Z-scores per year was 0.12 (2.28 to
4.24) among the controls and1.43 (0.29 to3.72) for the bisphosphonate group (P .0002). The greatest
improvement in BMD was observed in children who received therapy with bisphosphonates.
© 2007 American Society for Blood and Marrow Transplantation
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The attainment of sufﬁcient peak bone mass dur-
ng adolescence and early adulthood is an important
eterminant of long-term bone health, which corre-
ates with the risk for involutional osteoporotic frac-
ures [1, 2]. Therefore, it is of concern that almost half
f the children after hematopoietic cell transplantation
HCT) have reduced bone mineral density (BMD) [3].
ual-energy X-ray absorptiometry (DEXA) is the
ost common method for measuring BMD in chil-
ren now that age-related normative reference data
re available [4, 5]. The only study to report BMD in
hildren after HCT using DEXA scan technology
howed that BMD was signiﬁcantly lower than in
dults [6]. A large population-based cohort study
ndicates that fracture rates peak in childhood at age
4 years for boys and 11 years for girls with a (ombined rate of 133 per 10,000 person-years [7].
his compares with an estimated fracture rate
mong pediatric HCT recipients at our center of
72 per 10,000 person years (J.E. Sanders, unpub-
ished data), suggesting that reduced BMD may be
linically relevant.
Bone loss results from impaired bone mineraliza-
ion through disturbances of calcium and vitamin D
omeostasis, osteoblast, and osteoclast function,
nd deﬁciencies in growth or gonadal hormone se-
retion. Factors responsible for these disturbances
nclude chronic illness, glucocorticoid therapy, cra-
ial or total-body irradiation (TBI), and other cy-
otoxic agents given before HCT [8-14]. The lead-
ng cause of reduced BMD after HCT is prolonged
lucocorticoid therapy for graft-versus-host disease
GHVD) [8, 11, 14]. Bone loss is most rapid during
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P. A. Carpenter et al.684he ﬁrst 6 months of glucocorticoid therapy, and
ay occur with daily prednisone doses as low as
mg [15].
The National Institutes of Health Consensus rec-
mmendations for management of bone loss in adults
ith chronic GVHD (cGVHD) include intake of suf-
cient calcium and vitamin D, and therapy with sex
ormones or bisphosphonates, but the evidence for
isphosphonate use in children is limited [16, 17].
isphosphonates are analogs of pyrophosphate that
ind to hydroxyapatite crystals, and act primarily
hrough effects on enzymatic pathways in osteoclasts
o inhibit bone resorption but may also stimulate os-
eoblasts to promote bone formation [18]. The use of
isphosphonates in children has largely been conﬁned
o intravenous (IV) formulations like pamidronate,
ased upon experience in osteogenesis imperfecta, and
o a lesser extent in idiopathic juvenile osteporosis or
lucocorticoid-induced osteoporosis [19-25]. We re-
ort here the impact on BMD since we began adding
isphosphonate therapy to calcium and vitamin D
upplementation in children with reduced BMD after
CT.
ATIENTS AND METHODS
tudy Population and Design
This restrospective study included all pediatric
atients who survived at least 1 year after receiving an
llogeneic HCT at the Fred Hutchinson Cancer Re-
earch Center (FHCRC) between January 1997 and
une 2004. Patients or their responsible guardians,
onsented to the Protocol 999.02 approved by the
nstitutional review board of the FHCRC. Among the
38 children who survived 1 year, 173 had a screen-
ng DEXA scan and 55 did not. Ninety-nine (57%) of
he 173 screened patients had osteopenia or osteopo-
osis based on the following deﬁnition: osteopenia is
resent when a child’s BMD in g/cm2 equates to a
-score of 1.0 to 2.4 standard deviations below age-
elated mean BMD values, and osteoporosis is present
hen the Z-score is 2.5. Among these 99 patients,
8 had 2 or more DEXA scans during long-term
ollow-up and were selected for analysis. Patients were
hen grouped according to whether or not they re-
eived bisphosphonate therapy. Forty-eight patients
ho received supplemental vitamin D, and dietary
alcium with supplementation as appropriate (con-
rols), were compared to 18 patients who received
dditional therapy with bisphosphonate. Eight patients
ho failed to maintain BMD with calcium and vitamin
supplements subsequently received bisphosphonate
herapy and were analyzed twice in separate treatment
roups. 3edications for Prevention or Treatment
f Osteopenia
As part of long-term follow-up a clinical nutrition-
st assessed each child’s calcium and vitamin D intake
ased upon review of food records at almost every visit
hroughout the study interval. Supplemental calcium
as prescribed for children receiving glucocorticoid
herapy whenever daily calcium losses were increased,
r when elemental calcium intake was less than the
ecommended daily intake of 800 milligrams, 1200
illigrams, or 1500 milligrams, respectively, for ages
-5 years, 6-8 years, or9 years old [26]. Oral vitamin
supplements were recommended whenever dietary
itamin D intake was less than the recommended daily
ntake of 400 international units (IU) per day for
hildren aged 1-8 years or 400-800 IU per day for
hildren aged 9-18 years. Pamidronate was adminis-
ered monthly, at a dose of 1 milligram per kilogram
f body weight, and was diluted in normal saline to a
oncentration of 0.12-0.36 mg/mL before infusion
ver 2 to 3 hours. For convenience, orally adminis-
ered alendronate, or zoledronic acid by short i.v.
nfusion, were occasionally used as alternatives to
amidronate. Bisphosphonate was given until normal
MD was achieved and glucocorticoid therapy had
een discontinued. The initiation and management of
ormone replacement therapies were determined by a
ediatric endocrinologist.
one Mineral Density Assessment
Bone mineral density was measured by DEXA at
he lumbar spine and 1 or both proximal femurs using
he Lunar DPX-Alpha (Madison, WI) or the Hologic
DR-4500 (Waltham, MA), depending on which
achine was available at the time of baseline and
ollow-up evaluations. BMD was measured for 44
67%) of the 66 patients on both occasions using a
evice by the same manufacturer (Hologic 35 pa-
ients, Lunar 9 patients). Six of 18 patients treated
ith bisphosphonates and 16 of 48 patients from the
ontrol group had follow-up scans done on a DEXA
evice from the alternative manufacturer. Absolute
MD in g/cm2 was converted to standardized BMD
sBMD) expressed as mg/cm2 using accepted formulae
o account for the 12% reproducible variability in
MD when DEXA devices are used from different
anufacturers [27, 28]. Thus, sBMDSPINE  1000
0.9522Lunar DPX-L BMDSPINE) and sBMDSPINE
1000 (1.0755  Hologic QDR-2000 BMDSPINE).
ecause normative reference ranges for BMD using
he Hologic machine were not available across a broad
ange of pediatric ages, BMD analyses were conﬁned
o a comparison of average BMDmeasured at the 2nd,
rd, and 4th lumbar vertebrae.
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Bisphosphonate Therapy in Children 685tatistics
Descriptive statistics were tabulated for relevant
atient characteristics known to inﬂuence BMD. The
hi-square test was used to compare categoric and
he t-test was used to compare continuous data. The
ilcoxon test was used for the comparison of BMD
fter bisphosphonate with or without growth hor-
one therapy. For patients who were evaluated both
ith and without bisphosphonate, the data associated
ith each treatment period were assigned separately
o the appropriate treatment group. For simplicity,
he comparisons between groups were conducted as if
hey were fully independent.
ESULTS
aseline and Interval Characteristics
Fifty-eight patients predominantly received my-
loablative conditioning and marrow transplantation
able 1. Patient Demographics
Bisphosphonate Therapy N
umber of patients 4
ale gender 2
ge, years, median (range)
At transplant 10.0 (1
At baseline DEXA 10.4 (2
iagnosis at transplant
Acute lymphoblastic leukemia 2
Non-ALL 2
reparative regimen
Myeloablative TBI-containing 3
Myeloablative chemotherapy only 1
Nonmyeloablative
BI indicates total body irradiation; ALL, acute lymphoblastic leu
able 2. Interval Study Characteristics
Bisphosphonate Therapy
hronic GVHD
Yes, n (%) 33
No, n (%) 15
ertinent medications
Growth hormone, n
Thyroxine, n
Sex-hormone replacement, n
Prednisone <50% of interval*, n
Prednisone >50% of interval*, n (%) 27
alcium repletion
Not required, n
Partial interval supplementation
n
Median dose, mg (range) 358
Full interval supplementation
n
Median dose, mg (range) 1000
itamin D repletion
Full interval supplementation, n
VHD indicates graft-versus-host disease.
Patients were stratiﬁed according to whether the duration of prednisoneor leukemia at a median age of 10.6 years (range:
.1-17.9 years). Sixty percent of the study cohort was
ale and the proportion of males to females was
imilar for both groups (Table 1). Subjects with acute
ymphoblastic leukemia (ALL) had the greatest expo-
ure to glucocorticoids before HCT and were distrib-
ted evenly between groups. More children in the
ontrol group had received a transplant for a nonma-
ignant disorder. Cord blood recipients who received
lucocorticoids for acute GVHD (aGVHD) prophy-
axis numbered 5 among the controls, and 4 in the
isphosphonate group. cGVHD was present in 74%
f subjects and with a trend towards higher incidence
n those treated with bisphosphonates (P  .10). An
pparently greater proportion of children treated with
isphosphonates had received glucorticoid therapy for
ore than half of the study interval (P .17; Table 2).
ompared to the control group, more children who
eceived bisphosphonates were receiving growth hor-
Yes P
18 —
11 .96
) 11.3 (5.9-17.1) .04
) 12.0 (7.9-17.6) .006
8 .96
10 —
14 .62
3 —
1 —
DEXA, dual energy X-ray absorptiometry.
Yes P
16 (89) .10
2 (11) —
6 .01
1 .81
3 .19
3 —
15 (83) .17
2 —
1 —
00) 1000 (0-2400) —
—
15 —
00) 1500 (0-2400) —
18 —o
8
9
.1-17.9
.0-18.2
1
7
2
0
6No
(69)
(31)
4
2
3
21
(56)
10
7
(0-24
31
(0-24
48therapy spanned 50%, or 50%, of the study interval.
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P. A. Carpenter et al.686one (P  .01). At the time of the baseline DEXA
can, puberty was similarly advanced despite the median
ge being older among children receiving bisphospho-
ates compared to controls (Table 3). The median
eight velocity percentile by the end of the study did not
iffer signiﬁcantly between groups (P  .16).
All children received daily supplementation with
t least 400 IU of vitamin D (range 400-1200 IU).
welve children did not require calcium supplemen-
ation and 53 received partial or full supplementation
ith calcium based upon dietary intake and estimated
osses (Table 2).
Seventeen of the 18 children who were treated
ith bisphosphonate received pamidronate for the
ajority of the study interval. In 2 children, pamidro-
ate was later changed by the referring physician to
.v. zoledronic acid. Two teenage patients began ther-
py with oral alendronate, but 1 patient showed gas-
rointestinal intolerance and was changed to pamidr-
nate. Two other teenage patients were changed to
lendronate for the convenience of oral administration
ate in the course of therapy.
esponse to Therapy
The absolute change in BMD over the study in-
erval was examined by comparing sBMD to account
or differences in BMD that might have been attrib-
ted to the 1/3 of patients whose interval comparisons
ere based upon data from 2 different DEXA devices
Figure 1A). The median increase in sBMD was
reater in the bisphosphonate treated patients than in
he controls (P  .001, Table 3). To account for the
onger study interval in the bisphosphonate-treated
atients the change in sBMD was annualized and was
able 3. Interval Study Outcomes
Bisphosphonate Therapy
Outcome
No
Median
tudy Interval (days) 299
ge at follow-up DEXA (y) 11.5
eight velocity percentile 25th
ubertal progression
Tanner stage at baseline 1
Tanner stage at follow-up 1.5
tandardized BMD (mg/cm2)
Baseline 585
Follow-up 624
Increase in sBMD per year 60
sBMD/y, prednisone use <50%* 76
sBMD/yr, prednisone use >50%* 50
MD Z-score
Baseline 2.46 
Follow-up 2.79 
Increase in Z-score per year 0.12 
BMD indicates standardized bone mineral density; BMD, bone m
Patients were stratiﬁed according to whether the duration of pred
The median length of bisphosphonate therapy was 351 days (rang33% per year (range: 3% to 147%) for the tisphosphonate group compared to 10% per year
range: 26% to 41%) for the controls (P  .0002;
igure 1B). The annual increase in BMD was most
igniﬁcant among the recipients of bisphosphonates in
hom the duration of prednisone therapy was more
han half of the study interval (P  .0003). However,
here was a trend for bisphosphonate therapy to im-
rove sBMD among patients who received shorter
reatment with prednisone (P  .10). Because of the
mbalance in the proportion of patients who were
eceiving growth hormone (GH) in each group we
valuated the effect of GH on sBMD. The median
nnualized improvement in sBMD was 45% (range:
4% to 147%) for the 6 patients treated with bisphos-
honate plus GH (data not shown), and 31% (range:
% to 59%) for the 12 patients who received only
isphosphonate (P  .15).
To account for expected age-related improvement
n BMD we also examined the interval change in BMD
y comparing BMD standard deviation Z-scores. The
edian interval change in the Z-score was 0.12 for
he controls and 1.55 for patients who received
isphosphonates (Figure 2A). The annualized median
hange in the Z-score was 0.12 per year for the
ontrol group and 1.43 per year for the bisphospho-
ate group (P .0002; Figure 2B). Within the control
roup, the annualized median change in Z-score was
o different between children who did or did not
equire supplemental calcium and vitamin D (data not
hown).
Six children (12.5%) from the control group de-
eloped bone fractures at a median of 2.3 years (range:
.9-5.5 years) from baseline. Fractures were noted in
ertebral bodies, clavicle, and extremities, excluding
Yes
Pe Median Range
302 377† 226-788 .46
8.7 13.0 9.1-18.9 .009
99th <3rd <3rd->99th .16
2 1-5 .50
2 1-5 .43
982 623 364-1016 .28
1086 832 497-1083 .001
261 174 17-369 .0002
261 253 160-369 .10
192 169 17-332 .0003
1.16 3.57 5.13-0.86 .02
0.07 1.80 4.89-0.47 .06
4.24 1.43 0.29-3.72 .0002
ensity; DEXA, dual energy X-ray absorptiometry.
therapy spanned 50%, or 50%, of the study interval.
770).Rang
197-1
3.8-1
<3rd->
1-5
1-5
338-
364-
137-
0-
137-
5.15-
5.56-
2.28-
ineral d
nisonehe phalanges. Two children (11%) from the group
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Bisphosphonate Therapy in Children 687reated with bisphosphonates developed fractures.
ne child with severe osteoporosis at baseline (Z-
core, 5.13) had marked improvement in BMD but
ractured their right patella and radius during treat-
ent with bisphosphonate when they still had mod-
rately severe osteopenia (Z-score, 1.88). The other
hild whose Z-score improved from 3.37 to 0.47
eveloped an avulsion fracture of the ﬁfth metatarsal 4
onths after stopping bisphosphonate therapy.
rug-Related Toxicities
Monthly infusions of pamidronate were well tol-
rated with no related episodes of fever, hypocalcemia,
ypophosphatemia, or deterioration in serum creati-
ine. Grade 1 (CTC v 3.0) hypomagnesemia was
resent in many patients because of concomitant cal-
ineurin inhibitor therapy, but there was no discern-
ble acute or chronic disturbance of magnesium ho-
eostasis related to bisphosphonate infusions. One
atient developed a pruritic skin reaction with the ﬁrst
nfusion of pamidronate. Another patient developed
igure 1. Bone mineral density at baseline and after follow-up.
hown for the patients treated without (n  48) and with (n  18)
isphosphonates are: (A) the standardized BMD (sBMD) for each
atient, together with the median sBMD (ﬁlled large squares), at
aseline (pre) and at follow-up (post), and (B) the median, 25th, and
5th percentiles (box), and range of the rates of change of sBMD
whiskers).yspepsia with oral alendronate. No patients devel- (ped osteonecrosis of the jaw (ONJ). The develop-
ent of transverse bands of osteosclerosis as an
ncidental ﬁnding on plain ﬁlm radiographs of long
ones was common among the children who re-
eived bisphosphonates.
ISCUSSION
To the best of our knowledge, these results are the
rst to compare intervention with bisphosphonate
ersus standard calcium and vitamin D replacement as
herapy for children with reduced bone mineral den-
ity after HCT. In growing children, area-related
MD at the lumbar spine increases annually by
%-7% before puberty and 9%-13% during puberty
ased upon available normative data [29, 30]. We
ound that bisphosphonate therapy resulted in a 33%
edian annualized improvement in BMD; 3-fold
igher than in children receiving calcium and vitamin
igure 2. Annualized bone mineral density at baseline and after
ollow-up. Shown for the patients treated without (n 48) and with
n  18) bisphosphonates are: (A) the BMD Z-scores for each
atient, together with the median Z-score (ﬁlled large squares), at
aseline (pre) and at follow-up (post), and (B) the median, 25th, and
5th percentiles (box), and range of the rates of change of Z-scores
whiskers).
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P. A. Carpenter et al.688alone. In children, increases in bone volume result-
ng from normal growth are detected by DEXA as
ncreased areal-BMD, which may overestimate any
rue increase in bone mineralization because of ther-
py. However, our observation that BMD Z-scores
mproved in all but 1 patient who received bisphos-
honates suggests that age-related changes in bone
olume did not explain the positive effect that
isphosphonates had on areal-BMD. This degree of
mprovement allowed 6 children (33%) to shift from
he categories of osteoporosis (5) or osteopenia (1) to
ormal BMD, and more than half of the remaining
hildren shifted from the categories of osteoporosis
10) or osteopenia (1), to osteopenia (7), less severe
steoporosis (3), or unchanged (1).
The largest experience with pamidronate in chil-
ren is in osteogenesis imperfecta, a disease where the
igh rate of fractures causes pain and reduced ambu-
ation. In children with osteogenesis imperfecta, aver-
ge annual gains in BMD of at least 20%-40% are
chievable when cycles of bisphosphonate are admin-
stered i.v. at a dose of 1-3 mg per kilogram every
-3 months, and have been associated with a reduc-
ion in fracture rates by more than 60% [18-20, 25,
1-33]. At our center, the cumulative incidence of
one fractures at 5 years among 1180 children who
urvived at least 1 year after HCT was 8% (J. E.
anders, unpublished data). A controlled study to ad-
ress whether bisphosphonates might reduce fracture
ates in children after HCT is not feasible because
pproximately 400 patients per group would be re-
uired to have 80% power to detect a difference
etween a fracture rate of 5% and 10%. We presume
hat gains in BMD Z-scores of more than 1 standard
eviation are clinically relevant, and should reduce the
isk for fractures based upon results in other relevant
iseases.
It has been cautioned that prolonged administra-
ion of bisphosphonates may render bones more brit-
le or impair bone healing in children [34]. Partially
ounterbalancing this concern are studies in osteogen-
sis imperfecta, which have shown that bisphospho-
ates do not generally impair bone healing after frac-
ures and that intrinsic material properties of the bone
re not adversely affected, although delayed bone
ealing is more frequent after osteotomies [35, 36].
he characteristic transverse bands of osteosclerosis
hat we and others have observed on plain ﬁlm radio-
raphs appear to be of no clinical consequence and
isappear over time [37].
Bisphosphonate therapy was well tolerated in our
atients as has been the observation in other pediatric
iseases associated with reduced BMD. Many studies
ave reported a high incidence of fever with the initial
nfusion of pamidronate [19, 25]. We did not observe
his association, possibly because 89% of the children aere also receiving therapy with prednisone when the
nitial doses of pamidronate were administered.
Osteonecrosis of the jaw is a well-recognized and
otentially serious but rare complication of amino
isphosphonate therapy in adults (reviewed in [38]),
ut there have been no reports of ONJ in children
ho received pamidronate for osteogenesis imperfecta
39]. However, the incidence of ONJ may approach
% when bisphosphonates are administered i.v. and
onthly to adults for the management of bone malig-
ancy, and may occur more frequently in this setting
fter recent dentoalveolar trauma [38, 40]. Because
ral bisphosphonates have less frequently been impli-
ated as a cause of ONJ among patients without ma-
ignant bone disease, alendronate might be preferred
ver pamidronate in addition to the more convenient
oute of administration. Recent data indicate that oral
lendronate is tolerable and improves BMD when
iven weekly to children who are not concomitantly
eceiving glucocorticoid therapy [24, 41]. However,
he need to sit or stand upright for 30 minutes after
wallowing alendronate to prevent esophagitis, and
he risk for aspiration are practical limitations in small
hildren. Despite the greater association of ONJ with
.v. bisphosphonates, we favor medically supervised
.v. pamidronate over weekly oral bisphosphonate to
aximize compliance.
Our study had limitations associated with a retro-
pective analysis. Not all patients with reduced BMD
ere included in the analysis because they lacked a
ollow-up DEXA scan. Follow-up data in these pa-
ients may have altered our overall outcomes. Ideally,
omparison data would have been obtained on iden-
ical DEXA machines for all patients. However, this
roblem was reasonably addressed by applying recog-
ized formulae to correct for machine differences.
ertain pretreatment characteristics that might have
ffected outcomes were not balanced through ran-
omization into study groups. However, the only sig-
iﬁcant imbalance was the proportion of patients re-
eiving GH therapy and a trend towards more sex
ormone replacement in the bisphosphonate group.
o increase sample size we pooled patients who ini-
ially received bisphosphonate therapy and those who
ere treated with bisphosphonates after not respond-
ng to calcium and vitamin D alone. However, there
as no obvious difference between the median
hanges in annualized BMD Z-scores for the 8 pa-
ients who received bisphosphonate as secondary ther-
py compared to the 10 patients who received
isphosphonate as initial therapy (data not shown).
Growth hormone therapy may have contributed
o the overall improvement in BMD in the bisphos-
honate group because GH increases osteoblast activ-
ty and GH replacement therapy reverses osteopenia
n patients with hypopituitarism [42, 43]. Mauseth et
l [44] reported that BMD Z-scores of 23 children
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Bisphosphonate Therapy in Children 689ho had GH deﬁciency and osteopenia after HCT
mproved signiﬁcantly following treatment with GH,
nd adults with GH deﬁciency who were treated with
H had a reduced incidence of fractures [43]. Our
ample size was likely insufﬁcient to determine
hether the apparent greater improvement in BMD
or the 6 patients who received bisphosphonate plus
H compared to the 12 children who were treated
nly with bisphosphonates was real. However, the
1% median annualized improvement in sBMD for
ubjects who received only bisphosphonate was still
-fold higher than the controls, suggesting that
isphosphonate therapy is efﬁcacious by itself.
Our standard practice is to evaluate BMD in chil-
ren at 3 months after allogeneic HCT with an initial
ollow-up DEXA scan at 1 year. It is reasonable to
heck the serum calcium, magnesium, and 1,25-hy-
roxyvitamin D level in those patients who are shown
o have osteoporosis. Supplementation with calcium,
itamin D, and weight-bearing exercise based on guide-
ines of national organizations are recommended, al-
hough alone, these measures have not proved effective
n preventing osteopenia, osteoporosis, or fractures [26,
5]. Sex hormone replacement therapy has increased
one mass in both women and men, and is recom-
ended for adolescents if age appropriate [46, 47].
ur data provide reasonable evidence that bisphos-
honate therapy is tolerable and improves BMD in
hildren and adolescents after HCT. A large prospec-
ive study is needed to determine the incidence of
steopenia and osteoporosis in this population after
CT using DEXA, and to determine the optimal
ose regimen for pamidronate.
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